Bicara Therapeutics (BCAX) Shares Outstanding (Weighted Average) (2023 - 2026)

Bicara Therapeutics (BCAX) has 4 years of Shares Outstanding (Weighted Average) data on file, last reported at $60.7 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 11.5% year-over-year to $60.7 million; the trailing twelve-month figure through Mar 2026 stood at $60.7 million (up 11.5% YoY), and the FY2025 full-year result was $54.7 billion, up 225.35% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $60.7 million, down from $54.7 billion in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $54.7 billion in Q4 2025 and bottomed at $563483.0 in Q3 2023.
• The 4-year median for Shares Outstanding (Weighted Average) is $54.5 million (2025), against an average of $6.6 billion.
• The widest annual swing landed in 2025, when Shares Outstanding (Weighted Average) soared 8147.39%; it then climbed 11.5% in 2026.
• A 4-year view of Shares Outstanding (Weighted Average) shows it stood at $580.1 million in 2023, then soared by 2796.96% to $16.8 billion in 2024, then surged by 225.35% to $54.7 billion in 2025, then tumbled by 99.89% to $60.7 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $60.7 million (Q1 2026), $54.7 billion (Q4 2025), and $54.5 million (Q3 2025), per Business Quant data.

Peer Comparison